Clinical trial
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer
NCT00118040 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00118040 |
|---|---|
| Title | Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer |
| Official title | Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Bladder Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7 |
| Intervention type | Drug, Other, Procedure |
| Interventions | Genistein, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Therapeutic Conventional Surgery |
| Enrollment | 60 |
| Start date | Jun 24, 2005 |
| Primary completion | Aug 15, 2010 |
| Completion | Aug 15, 2010 |
| First posted | Jul 11, 2005 |
| Last update posted | Jun 10, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: